40 results about "Anesthesia analgesia" patented technology

The invention belongs to the technical field of medical apparatuses and instruments and provides a nerve-blocking puncture catheter needle with an adjustable puncture head. The catheter needle mainly consists of a puncture catheter and a puncture needle core. During operation, the puncture needle core is sleeved by the puncture catheter, and the sharp end of the puncture needle core extends out of a port of the puncture catheter and has sharpness. Under the ultrasonic guidance, the sharp end of the puncture needle core can return to the puncture catheter through adjustment and control when the catheter is close to the target nerve, and the catheter needle loses the sharpness but still has toughness and can continue to penetrate the fascia tissue to be close to the nerve till the catheter needle touches the nerve. Due to the fact that a needle point returns back to the catheter and loses the sharpness, the nerve is not hurt, the catheter needle reaches a target position, the puncture needle core can be directly removed, and the puncture catheter is indwelt around the nerve for future anesthesia medicine application or anesthesia analgesia treatment and other applications.

The invention relates to an anesthesia analgesia drug composition. The drug composition comprises a compound drug composition which can serve as a sedative hypnotic drug and contains rRemimazolam, derivatives of rRemimazolam and a narcotics analgesic.

The invention belongs to the field of anesthetics, and in particular relates to a compound anesthetic and a preparation method thereof. Raw materials include: propofol, methyl eugenol, citric acid, mint ice, nine layers of wind, red peony root, ethanol, lecithin, water, prepared after extraction and mixing of active ingredients, the compound anesthetic has good It has excellent anesthesia and analgesic effects, small side effects, and simple and easy preparation method.

Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen; a narcotic analgesic; colloidal silicon dioxide; a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose; a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate; a binder consisting of an akylhydroxy methylcellulose; a starch; and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process; (b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material; and (c) compressing the blend into a tablet.

The invention relates to the field of medicines, in particular to a long-acting and low-addiction HNK derivative for treating depression, including complex regional pain syndrome (CRPS), and a preparation method thereof. The compound of the present invention has the structure shown in formula I, and has the functions of antidepression, anesthesia, analgesia, improvement of cognitive function, lung protection, prevention or treatment of amyotrophic lateral sclerosis or prevention or treatment of complex regional pain syndrome. Compared with the existing known HNK compounds, the compound of the present invention has a longer drug effect time, and the compound of the present invention basically does not produce addiction.

The invention provides a preparation method of microspheres loaded with anesthetic and analgesics, and its products and uses. The preparation method of the anesthetic and analgesic-loaded microspheres includes the following steps: (1) dissolving the anesthetic and analgesic drug in water to form an inner water phase; dissolving the degradable high molecular polymer and the oil phase emulsifier in an organic solvent to form an oil phase; dissolve the stabilizer in water to form an outer water phase; (2) mix the inner water phase and oil phase obtained in step (1), and obtain W after emulsification 1 / O type emulsion; (3) the outer water phase obtained in step (1) and the W obtained in step (2) 1 / O type emulsion mixed, emulsified to obtain W 1 / O / W 2 Type pre-recombination emulsion, filtered through a microporous membrane, and then solidified to obtain anesthetic and analgesic-loaded microspheres. The preparation method of the invention can effectively reduce the escape of drug molecules, improve the entrapment rate of the drug, and further increase the drug loading capacity. At the same time, the particle size and structure of the microspheres are controllable.

A system for inducing a Pavlovian association of a scent with a state of less-than-moderate pain, to thereby minimize perceived pain, and to reduce the need for narcotic analgesics. The system includes at least a physiological sensor configured to detect at least one physiological parameter of the user. The physiological parameter of the user may include heart rate variability, blood pressure, galvanic skin response, movement, facial expression and the like. After detection of the physiological parameter, an activation signal is then transmitted to an automatically activated scent diffuser, which diffuses a scent, as a function of the electronic activation signal. The scent may include one or more scent liquids, such as perfumes, essential oils, or the like. Activation of the scent diffuser is maintained by a control circuit that receives the detection signal from the at least one physiological sensor, ascertains that the user has transitioned to a state of less-than-moderate pain, and transmits a signal to the automatically activated scent diffuser. After an association, wherein association further includes conditioning, is created in the user, by iterative performance of the foregoing steps, the user can manually activate a second scent source, in order to trigger a conditioned reflex to assist the user in reducing pain levels.

The invention discloses the application of a combination of polyethylene glycol and local anesthetic in non-narcotic analgesia. In the present invention, the local anesthetic is made into a prodrug or a sustained-release preparation, wherein the high molecular polymer in the prodrug such as polyethylene glycol is covalently bonded with the local anesthetic, and the auxiliary material in the sustained-release preparation plays a sustained-release role Combined with local anesthetics in a non-covalent bond, after administration, there is no anesthesia and analgesic effect before the free local anesthetic is released, and the analgesic effect is released after the free local anesthetic is released, and the local anesthetic of the present invention The prodrug or sustained-release preparation of the drug releases the drug slowly, which can keep the drug concentration stable and lasting within the effective concentration range of non-narcotic analgesia, while significantly reducing the clinical adverse reactions of local anesthetics and reducing the number of administrations. , can achieve long-acting non-narcotic analgesic effect, enhance the effectiveness of the drug, and expand the clinical application range of local anesthetics.

A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg / ml-160 mg / ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and / or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v / v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v / v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.